Le Lézard
Classified in: Health, Business
Subjects: FNC, OTC

MYM Announces Closing of Second Tranche of Non-brokered Financing


VANCOUVER, British Columbia, Nov. 6, 2017 /CNW/ -- MYM Nutraceuticals Inc., (CSE: MYM) (MYM.CN) (OTC:MYMMF) (the "Company" or "MYM") is pleased to announce that it has closed the second and final tranche of its non-brokered private placement of 771,000 units at a price of $0.50 per unit for gross proceeds of $385,500

Each unit in the private placement is made up of one common share and one transferable share-purchase warrant, exercisable at $1.00 for a period of one year. The securities will be subject to a four-month hold period under applicable securities laws.

Finder's fees totaling $12,462.50 were paid on the financing.

The Company intends to use the net proceeds from the private placement for general working capital and corporate purposes.

About MYM

MYM Nutraceuticals Inc. is an innovative company focused on acquiring Health Canada licenses to produce and sell high-end organic medicinal cannabis supplements and topical products.  To ensure a strong presence and growth potential within the industry, MYM is actively looking to acquire complementary businesses and assets in the technology, nutraceuticals and CBD sectors. MYM shares trade in Canada, Germany and the USA under the following symbols: (CSE: MYM) (OTC: MYMMF) (FRA: 0MY) (DEU: 0MY) (MUN: 0MY) (STU: 0MY).

On behalf of the board

Rob Gietl, CEO
MYM Nutraceuticals Inc.
www.mymarijuana.ca

This news release may contain forward-looking statements based on assumptions and judgments of management regarding future events or results. Such statements are subject to a variety of risks and uncertainties which could cause actual events or results to differ materially from those reflected in the forward-looking statements. The company disclaims any intention or obligation to revise or update such statements. For a description of the risks and uncertainties facing the Company and its business and affairs, readers should refer to the Company's Management's Discussion and Analysis and other disclosure filings with Canadian securities regulators, which are posted on www.sedar.com.

This news release does not constitute an offer to sell or solicitation of an offer to buy any of the securities described herein and accordingly undue reliance should not be put on such. Neither the Canadian Securities Exchange (CSE or CNSX Markets), nor its Regulation Services Provider (as that term is defined in policies of the CSE), accepts responsibility for the adequacy or accuracy of this release.

This news release does not constitute an offer to sell or a solicitation of an offer to buy any of the securities described herein in the United States. The securities described herein have not been registered under the United States Securities Act of 1933, as amended (the "U.S. Securities Act"), or any state securities law and may not be offered or sold in the "United States", as such term is defined in Regulation S promulgated under the U.S. Securities Act, unless registered under the U.S. Securities Act and applicable state securities laws or an exemption from such registration requirements is available.

Investor Relations
Terry Brown
+1-855-696-2261

SOURCE MYM Nutraceuticals Inc.


These press releases may also interest you

at 07:56
Medtronic plc , a global leader in healthcare technology, today announced that the U.S. Food and Drug Administration (FDA) has approved the Inceptivtm closed-loop rechargeable spinal cord stimulator (SCS) for the treatment of chronic pain. Inceptiv...

at 07:55
The "KEYTRUDA Market Size, Forecast, and Emerging Insight - 2032" report has been added to ResearchAndMarkets.com's offering. The report provides comprehensive insights about KEYTRUDA for ovarian cancer in the seven major markets. A detailed...

at 07:50
The "Peptide Synthesis Market: Industry Trends and Global Forecasts, Till 2035: Distribution by Type of Peptide Synthesis Method, Type of Chemical Synthesis, Contract Manufacturing Organization Size, Key Geographical Regions" report has been added to...

at 07:45
The "Laboratory Filtration Equipment - Global Strategic Business Report" report has been added to ResearchAndMarkets.com's offering. Global Laboratory Filtration Equipment Market to Reach $3 Billion by 2030 The global market for Laboratory...

at 07:40
The "Global Weight Loss Drugs Market: Analysis By Product Type, By Drug Type, By Distribution Channel, By End User, By Region, Size and Trends with Impact of COVID-19 and Forecast up to 2029" report has been added to ResearchAndMarkets.com's...

at 07:35
Arrowhead Pharmaceuticals, Inc. today announced its plan to host a 2024 Summer Series of R&D webinars that highlight multiple clinical stage RNA interference (RNAi) based medicines that utilize the company's proprietary Targeted RNAi Molecule...



News published on and distributed by: